spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Dual Anti-Platelet Therapy 

 HSMN NewsFeed - 6 Sep 2022
Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX(TM) LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 30 Jun 2021
Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 29 Jan 2020
CytoSorb(R) is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U.
Devices Regulatory Product Launch
 HSMN NewsFeed - 5 Oct 2015
Boston Scientific Receives FDA Approval For SYNERGY(TM) Bioabsorbable Polymer Drug-Eluting Stent System
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 19 Jun 2013
AngioScore Announces Completion of Enrollment in Drug-Coated AngioSculpt(R) Scoring Balloon Catheter First-in-Human Study
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Oct 2012
PROMUS Element(TM) and PROMUS Element(TM) Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 20 Aug 2012
Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 16 May 2012
Elixir Medical Announces Excellent Results from DESolve I First-In-Man Study for the Fully Bioresorbable Drug Eluting Coronary Scaffold System
Devices Interventional Cardiology
 HSMN NewsFeed - 15 May 2012
Abbott's XIENCE PRIME(TM) and XIENCE V(R) Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 15 May 2012
Svelte Medical Systems Announces Final Patient Treated in the DIRECT Drug-Eluting Stent Study
Devices Interventional Cardiology
 HSMN NewsFeed - 14 Dec 2011
AngioScore Announces Successful Initiation of Enrollment in Drug-Coated AngioSculpt(R) Scoring Balloon Catheter First-in-Human Study
Devices Interventional Cardiology
 HSMN NewsFeed - 18 May 2011
Favorable Clinical Study Results Reported With Dual Anti-Platelet Therapy After LAA Closure With WATCHMAN(R) Device
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Feb 2011
Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeich's Genous Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Jan 2011
Abbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold for Treatment of Coronary Artery Disease
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 20 Apr 2010
OrbusNeich Announces Full Availability of Genous(TM) Bio-engineered Cobalt Chromium Stent Following CE Mark Approval
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 31 Aug 2009
First Patient Enrolled in CYPRESS, a Dual Antiplatelet Therapy Trial with the CYPHER(R) Sirolimus-Eluting Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Aug 2009
Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 19 May 2009
NEVO Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus Liberte Stent in Pivotal Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Oct 2008
12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions
Devices Interventional Cardiology
 HSMN NewsFeed - 7 Oct 2008
CeloNova BioSciences to Showcase the CE-Marked CATANIA(TM) Coronary Stent System Featuring NanoThin Polyzene(R)-F at TCT Debut
Devices Interventional Cardiology
 HSMN NewsFeed - 21 Jan 2008
Super-Thin Drug-Free Coating 'Hides' Stent as It Unblocks Heart Arteries
Devices Interventional Cardiology
 HSMN NewsFeed - 20 Jan 2008
CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Oct 2007
FDA Advisory Committee Recommends Medtronic's Endeavor(R) Drug-Eluting Stent for Approval
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 4 Apr 2007
Volcano Corporation Reports Use of IVUS Increasing as Physicians Refocus on Stent Technique
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Mar 2007
Two-Year Patient Registry Results Support Safety and Efficacy of CYPHER(R) Sirolimus-Eluting Coronary Stent in 'Real World' Uses
Devices Interventional Cardiology
 HSMN NewsFeed - 12 Feb 2007
Multiple Articles in the New England Journal of Medicine Confirm On-Label, Long-Term Safety and Efficacy of the CYPHER(R) Sirolimus-Eluting Coronary Stent Compared to Bare Metal Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Oct 2006
Cordis to Study Impact of Contributing Factors to Stent Thrombosis in Expansion of 30,000-Stent Patient Registry
Devices Interventional Cardiology
 HSMN NewsFeed - 11 May 2006
Conor Medsystems Initiates RAPID Clinical Study for First Pimecrolimus Drug-Eluting Stent
Devices Interventional Cardiology
Return to NewsFeed  

 Additional items found! 2

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 2 additional stories matching:
Dual Anti-Platelet Therapy
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.